NASDAQ:ANAB - Nasdaq - US0327241065 - Common Stock - Currency: USD
23.32
+0.5 (+2.19%)
The current stock price of ANAB is 23.32 USD. In the past month the price increased by 14.09%. In the past year, price decreased by -6.94%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.07 | 327.76B | ||
AMGN | AMGEN INC | 13.37 | 149.21B | ||
GILD | GILEAD SCIENCES INC | 13.85 | 133.35B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.63B | ||
REGN | REGENERON PHARMACEUTICALS | 11.79 | 56.39B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.38B | ||
ARGX | ARGENX SE - ADR | 98.79 | 34.69B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.82 | 28.86B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.26B | ||
NTRA | NATERA INC | N/A | 23.47B | ||
INSM | INSMED INC | N/A | 19.29B | ||
BIIB | BIOGEN INC | 7.98 | 18.51B |
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 136 full-time employees. The company went IPO on 2017-01-26. The firm is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The firm's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
ANAPTYSBIO INC
10770 Wateridge Circle, Suite 210
San Diego CALIFORNIA 92121 US
CEO: Hamza Suria
Employees: 136
Phone: 18583626295
The current stock price of ANAB is 23.32 USD. The price increased by 2.19% in the last trading session.
The exchange symbol of ANAPTYSBIO INC is ANAB and it is listed on the Nasdaq exchange.
ANAB stock is listed on the Nasdaq exchange.
18 analysts have analysed ANAB and the average price target is 43.45 USD. This implies a price increase of 86.33% is expected in the next year compared to the current price of 23.32. Check the ANAPTYSBIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ANAPTYSBIO INC (ANAB) has a market capitalization of 685.14M USD. This makes ANAB a Small Cap stock.
ANAPTYSBIO INC (ANAB) currently has 136 employees.
ANAPTYSBIO INC (ANAB) has a support level at 23.17 and a resistance level at 23.32. Check the full technical report for a detailed analysis of ANAB support and resistance levels.
The Revenue of ANAPTYSBIO INC (ANAB) is expected to grow by 18.63% in the next year. Check the estimates tab for more information on the ANAB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ANAB does not pay a dividend.
ANAPTYSBIO INC (ANAB) will report earnings on 2025-08-04, after the market close.
ANAPTYSBIO INC (ANAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.85).
The outstanding short interest for ANAPTYSBIO INC (ANAB) is 33.02% of its float. Check the ownership tab for more information on the ANAB short interest.
ChartMill assigns a technical rating of 8 / 10 to ANAB. When comparing the yearly performance of all stocks, ANAB turns out to be only a medium performer in the overall market: it outperformed 63.49% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to ANAB. ANAB has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months ANAB reported a non-GAAP Earnings per Share(EPS) of -4.85. The EPS increased by 21.01% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -33.32% | ||
ROE | -413.34% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to ANAB. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of -3.83% and a revenue growth 18.63% for ANAB